Novadaq Technologies Inc.TSX: NDQ

Novadaq to present at Pacific Growth Equities Life Sciences Growth Conference

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, June 6 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, announced today
that Dr. Arun Menawat, President & Chief Executive Officer, will present the
corporate story, technology and highlights at the Pacific Growth Equities Life
Sciences Growth Conference. The conference runs from Monday, June 12 through
Wednesday, June 14 at the InterContinental Mark Hopkins Hotel in San
Francisco. Dr. Menawat presents at 10:30 am on Tuesday, June 13 in the
California Room.

About Novadaq
Technologies Novadaq Technologies Inc. (TSX: NDQ) develops and
commercializes medical devices based on its proprietary imaging platform for
the diagnosis and treatment of human vascular, ophthalmic, and neurologic
diseases and conditions. Novadaq's SPY(R) Intra-operative Imaging System,
commercially available worldwide, enables cardiac surgeons to visually assess
coronary vasculature and bypass graft functionality during the course of open-
heart bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is
aimed at the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery, LUNATM
is being developed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases